Last updated: July 1, 2026
Litigation summary and analysis: Hoffmann-La Roche Inc. v. Airis Pharma Private Limited (1:17-cv-07912)
Hoffmann-La Roche Inc. (Roche) v. Airis Pharma Private Limited (Airis) under case number 1:17-cv-07912 is a federal patent infringement action filed in the U.S. District Court for the District of New Jersey. The case is part of the Paragraph IV / Hatch-Waxman ecosystem tied to Roche’s small-molecule drug patent estate, with Airis positioned as the challenger/ANDA filer. Public docket access is required to verify the exact asserted patents, the filing date of the complaint, the procedural posture (dismissal, settlement, consent judgment, or ongoing litigation), and the final resolution terms.
What patents were asserted in Hoffmann-La Roche v. Airis Pharma 1:17-cv-07912?
Answer (from available context): The matter is a Roche infringement case against Airis in a Hatch-Waxman setting, but the specific asserted patent numbers and claims are not present in the provided information, so the patent list cannot be stated accurately.
Which patent estate is this case linked to (drug, Orange Book listing, Paragraph IV basis)?
Answer (from available context): The case is described at a high level as a Hatch-Waxman challenge connected to Roche’s Orange Book-listed patent coverage. The drug identity and Orange Book drug-product mapping (which NDA, which Orange Book patents, which registration) are not contained in the provided information, so they cannot be enumerated.
How were patents typically pleaded in Roche v. ANDA challengers?
In Roche-style Hatch-Waxman suits involving generic entrants, asserted patents typically include one or more of:
- Composition of matter patents (active ingredient)
- Formulation patents (salt, polymorph, solid-state form, dosage form)
- Method-of-use patents (indication-specific use)
- Manufacturing or process patents (if applicable)
The exact mix in 1:17-cv-07912 is not confirmable from the supplied input.
When did Hoffmann-La Roche sue Airis Pharma (complaint and service timeline)?
Answer (from available context): The case number indicates filing in 2017 (1:17-cv-07912), but the precise complaint filing date, service dates, and early scheduling order milestones cannot be provided accurately without docket data.
What were the key early procedural steps?
For Hatch-Waxman patent cases, key steps usually include:
- Complaint filing
- Answer and potential motions to dismiss
- Claim construction schedule
- Infringement and invalidity expert workups
- Markman hearing timing
- Summary judgment rounds (if pursued)
The procedural dates for this specific case require docket verification.
What was the litigation posture at the end (dismissed, settled, judgment, or ongoing appeal)?
Answer (from available context): The resolution status is not specified in the provided information. A correct litigation-end summary requires the docket outcome (final judgment, dismissal with prejudice, settlement with consent judgment, or withdrawal).
If there was a settlement, what did it typically cover?
When Hatch-Waxman cases settle, terms commonly include:
- Staggered launch dates tied to patent expiration or agreed non-infringement windows
- License grant scope (often limited to the ANDA product as described)
- Covenants not to sue for the covered period
- Trigger conditions (FDA approval, shipment caps, design changes)
- Alternative dispute mechanism (usually not public in full detail)
No settlement terms can be stated without docket filings or publicly released agreements.
What Paragraph IV certifications and ANDA facts drove Roche’s claims?
Answer (from available context): The litigation is consistent with a Paragraph IV framework, but the actual ANDA number, the certified patents, and whether Airis made No Paragraph IV, Paragraph III, Paragraph II, or a specific Paragraph IV certification structure cannot be confirmed from the provided input.
Who is the ANDA applicant and what product was at issue?
Answer (from available context): Airis is the defendant/ANDA challenger in the caption context, but the ANDA product name, dosage form, strength, and label description are not specified.
How strong is Roche’s patent estate in this case (validity and infringement risk)?
Answer (from available context): Strength depends on the specific asserted patents, their remaining life, claim scope, and prior art landscape. The provided information does not include asserted patent numbers, expiration dates, or claim constructions, so a strength rating cannot be produced.
Common infringement and invalidity fault lines in Roche suits
Typical areas litigated in Roche ANDA cases include:
- Infringement based on chemical identity, polymorph/salt form, and bioequivalence attributes
- Indefiniteness and written description issues
- Anticipation/obviousness based on prior patents, publications, and formulation disclosures
- Enablement and best mode equivalents (where applicable)
- Obviousness-type double patenting
No case-specific legal findings are available in the supplied input.
What claim construction issues mattered most in 1:17-cv-07912?
Answer (from available context): Claim construction outcomes drive infringement and validity. The docket record is needed for:
- The disputed terms
- The court’s constructions
- Whether constructions favored Roche or Airis
Those details are not included.
Was there any Federal Circuit or district court motion practice that changed the trajectory?
Answer (from available context): Case-specific motions are not described in the provided input. Accurate identification requires:
- Motions to dismiss (12(b)(6) or 35 U.S.C. challenges)
- Jurisdictional challenges
- Transfer motions
- Stay motions pending other litigation
- Summary judgment or Daubert motions
- Appeals, mandamus, or remand
What generic entry risks existed for Airis after Roche filed?
Answer (from available context): Hatch-Waxman risk exposure typically comes from:
- In-suit injunction risk under 35 U.S.C. § 271(e)(4)
- Potential design-around constraints if claim coverage is broad
- “At-risk” launch exposure after a judgment of non-infringement/invalidity or settlement terms
But the actual risk timing (when Roche could block approval and whether it did) depends on:
- Final judgment timing
- Settlement effective date
- FDA approval timeline
- The remaining life of asserted patents
None are provided.
How does this case compare with other Roche vs. ANDA litigation (industry pattern)?
Answer (from available context): Without the asserted patents and outcome, a true comparative analysis cannot be made. A qualitative comparison is possible only at a generic level:
- Roche’s frequently asserted baskets in small-molecule estates usually include core composition and selectivity/formulation improvements.
- Litigation often turns on whether the generic’s salt/polymorph and manufacturing method satisfy the claim limitations.
This is not case-specific.
Key case record items typically needed for an investment-grade litigation brief (missing from supplied input)
| Item |
Why it matters |
Status in provided info |
| Asserted patent numbers |
Defines claim scope and expiration-based blocking |
Not provided |
| Drug/Orange Book mapping |
Connects patents to FDA product and certification strategy |
Not provided |
| ANDA number |
Links FDA record to litigation |
Not provided |
| Complaint date and court assignment |
Defines timeline and procedural posture |
Not provided |
| Motion outcomes (dismissal, stay, claim construction) |
Determines infringement/validity trajectory |
Not provided |
| Final resolution |
Determines launch rights and ongoing risk |
Not provided |
| Settlement terms or consent judgment |
Determines launch dates and covenants |
Not provided |
| Injunction or court-ordered relief |
Impacts at-risk launch window |
Not provided |
Key Takeaways
- 1:17-cv-07912 is a Roche vs. Airis Hatch-Waxman patent infringement case filed in 2017 in federal court.
- A complete, business-actionable litigation summary requires the asserted patent list, the drug/Orange Book mapping, and the case outcome.
- Those critical facts are not present in the provided input, so a definitive patent-by-patent or outcome-based analysis cannot be produced accurately.
FAQs
-
What does a Roche v. Airis case typically claim under Hatch-Waxman?
Generally infringement under 35 U.S.C. § 271(e)(2) tied to ANDA Paragraph IV certifications, with potential relief under § 271(e)(4) if at-risk launch occurs.
-
Does a dismissal in a Roche generic case mean the patents are invalid or non-infringed?
Not necessarily. Dismissals can follow settlement, voluntary dismissal, procedural defects, or non-substantive resolutions.
-
How do settlement agreements in Roche vs. ANDA cases usually affect launch timing?
They commonly set defined launch dates, covenant terms, and sometimes design-around commitments tied to specific patent expiration windows.
-
What evidence is usually decisive in Roche formulation/polymorph disputes?
Expert analytical testing of the generic’s solid-state form, salt identity, and manufacturing controls, aligned to the asserted formulation claim limitations.
-
What is the practical impact of claim construction on generic entry risk?
Constructions narrow or broaden literal infringement and can determine whether invalidity defenses succeed on the relevant claim scope.
References (APA)
- U.S. District Court, District of New Jersey. Hoffmann-La Roche Inc. v. Airis Pharma Private Limited, No. 1:17-cv-07912. (Docket and filings not provided in the input).
